Form 4: Supernus Pharmaceuticals Director Exercises and Sells Shares
SEC Form 4
Director Georges Gemayel exercised stock options and sold shares of Supernus Pharmaceuticals on November 8, 2024.
Summary
- On November 8, 2024, Georges Gemayel, a director of Supernus Pharmaceuticals, exercised stock options to acquire 10,787 shares of common stock at a price of $11.46 per share.
- Simultaneously, Gemayel sold 10,787 shares of Supernus common stock at a weighted average price of $36.3, with individual sales ranging from $36.01 to $36.57.
- Following these transactions, Gemayel directly owns 13,315 shares of Supernus common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company directors. It's common for directors to exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 03/23/2016 | Date the Director Stock Option was granted |
| 03/23/2025 | Expiration date of the Director Stock Option |
| 11/08/2024 | Date of stock option exercise and share sale |
| 11/12/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.